Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Hyperliquid BTC major positions liquidated over 100 millions USD in shorts

Hyperliquid BTC major positions liquidated over 100 millions USD in shorts

AiCoinAiCoin2026/06/04 12:51
Show original
According to PRO "Large Transactions" monitoring, BTC experienced a short-term rebound of over 2.4%. During this period, there were 27 major buy orders executed at market price on Hyperliquid contracts, with a total transaction amount reaching $101 million. Based on the open interest difference, the open interest continued to decrease during these major trades, indicating that the main force was primarily buying to cover short positions. According to the latest data, the main force once again executed market trades worth $8.42 million. To determine the specific trading direction, you can set the "Large Transactions" and "Open Interest Difference" indicators for analysis. Special reminder: This round of rebound was not accompanied by an increase in open interest, so it is recommended to focus on the major spot trades and whether there will continue to be large buy orders, in order to confirm the intentions of main funds.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage